AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection
Description: ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian puncture
Description: Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
Study NCT03291821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation genetic test
Description: The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
Study NCT03291821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic test
Description: The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo transfer
Description: Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
Study NCT03291821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy test
Description: A pregnancy test is used to determine whether a woman is pregnant.
Study NCT03291821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: A pregnancy test is used to determine whether a woman is pregnant.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo freezing
Description: Embryo freezing is a method for cryopreserving embryos.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo freezing
Description: Embryo freezing is a method for cryopreserving embryos.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo thawing
Description: Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo thawing
Description: Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
Study NCT00667225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin 0.7%
Description: Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
Study NCT02248818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8108
Description: Drug: AZD8108 Single or Multiple doses administered orally as a solution.
Study NCT02248818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
Study NCT02912546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
Study NCT04061369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat meal
Description: Meal consisting of conventional foods that is low (20% of energy) in fat calories.
Study NCT04061369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate fat meal
Description: Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
Study NCT04061369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: Meal consisting of conventional foods that is high (60% of energy) in fat calories.
Study NCT04061369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat liquid meal
Description: Liquid meal that is high (60% of energy) in fat calories.
Study NCT02075281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: Glucagon-like peptide-1 analogue
Study NCT02075281 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04407689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
Study NCT04407689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) placebo (normal saline) at the same frequency
Study NCT04609488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Surfactant assessment
Description: To determine surfactant levels in lung fluid
Study NCT01877148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
Study NCT01877148 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
Study NCT01877148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
Study NCT01877148 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
Study NCT00508053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small stitches
Study NCT00508053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mass closure
Study NCT05234840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: 1. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP
Study NCT05234840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 40 mg triamcinolone with 1% lidocaine, total of 2 ml
Study NCT04497389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Fluid
Description: Patients will receive 10ml intravenous hAF each day for 5 consecutive days.
Study NCT01796626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 ResurFX module
Description: The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
Study NCT00876564 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trauma patients
Study NCT03843853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 d1
Study NCT03843853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14
Study NCT03843853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg d1
Study NCT04293003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasting
Description: 6-hour fasting
Study NCT04293003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate
Description: Consumption of a zero-carbohydrate breakfast
Study NCT04293003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean
Description: Consumption of a Mediterranean-type breakfast
Study NCT03297177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose
Description: Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
Study NCT03297177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Closed System, Digestive Isolation \& Concentration of AD-cSVF
Study NCT03297177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline Infusion
Description: Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
Study NCT02136134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
Study NCT02136134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE (Bortezomib)
Description: VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
Study NCT02136134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VELCADE (Bortezomib)
Description: VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
Study NCT02136134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
Study NCT02136134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
Study NCT01450384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT01450384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01450384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01450384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT02750449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sun screening Sport Lotion, (BAY987516)
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
Study NCT02750449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: This site is patched without treatment as control
Study NCT02591953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guidance
Description: Using ultrasound-guidance to perform a corticosteroid injection
Study NCT02591953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-guidance
Description: Using landmark-guidance to perform a corticosteroid injection
Study NCT02591953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Corticosteroid used in injection (40 mg)
Study NCT02591953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Corticosteroid used in injection (40 mg)
Study NCT02591953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1%
Description: Anesthesic used in injection
Study NCT02591953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Description: Anesthesic used in injection
Study NCT01588964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
Study NCT04542967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out.
Study NCT04677218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL reconstruction with retensioned hamstring autograft
Description: After diagnostic arthroscopy, an oblique, 5-cm oblique skin incision is made below the joint line over the proximal edge of the pes anserine.Then fascia will be incised the fascia in an L-shaped fashion. After the releasing the distal end of tendons ,tendons will be harvested in their direction via tendon strippers.During the graft preparation phase firstly femoral tunel will be drilled from AM portal with knee flexed to 120 degrees. The drill will be aligned parallel to the tibial plateau and exit through LFC.Then tibial guide wire will be sent from graft incision to the tibial tunel and drilled for desired direction.Once the adjustable loop button is deployed to the graft, it will be pulled through the tunnels and the button is slipped on lateral femoral cortex. Then tibial fixation will be provided with one bioabsorbable screw and staple.After tibial fixation, the femoral loop will be retensioned in group 2 patients.
Study NCT04677218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic ACL reconstruction with retensioned and knotted hamstring autograft
Description: After the same preparation procedure as in retensioned autograft group, after tibial fixation of graft, femoral loop will be retensioned and knotted in 3. group .
Study NCT01355276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinitapride
Description: cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
Study NCT01355276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: 10 mg for each dose ,30 mg/daily, for 4 weeks
Study NCT02548975 — intervention group
Intervention type: DRUG
Intervention: Statin, beta blocker
Description: Patients receiving either statin or beta blockers prior to cardiac surgery.
Study NCT03076112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
Study NCT03076112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
Study NCT00929838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Knowledge/Information
Description: This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
Study NCT00929838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation/Behavioral Skills
Description: This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
Study NCT00929838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Intervention
Description: This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
Study NCT00929838 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
Study NCT01014598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intra-arterially via isolated lung suffusion
Study NCT01014598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03842904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimbow pMDI
Description: Clinical Trial of an Investigational Medicinal Product (CTIMP)
Study NCT03842904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostair pMDI
Description: Clinical Trial of an Investigational Medicinal Product (CTIMP)
Study NCT01438138 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT03863847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: The patients will receive neurofeedback on pain related brain-activity, and through training, learn to control said brain-activity.
Study NCT03863847 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The patients will receive sham neurofeedback on non-pain related brain-activity, and through training, learn to control said brain-activity.
Study NCT01296412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: 100 mg tablet, orally, once daily.
Study NCT01296412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: 0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
Study NCT01296412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
Study NCT01296412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin tablets at a dose of ≥1500 mg per day
Study NCT01296412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablets at a dose of ≥1500 mg per day
Study NCT00610181 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
Study NCT02548975 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary bypass
Description: Patients exposed to cardiopulmonary bypass during cardiac surgery.